Immunization
COVID-19 Vaccination and Intent for Vaccination of Adults With Reported Medical Conditions
Individuals with certain medical conditions are at substantially increased risk for severe illness from COVID-19. The purpose of this study is to assess COVID-19 vaccination among U.S. adults with reported medical conditions.Hepatitis B Vaccination Among Adults With Diabetes Mellitus, U.S., 2018
Hepatitis B vaccination is routinely recommended for adults with diabetes mellitus aged <60 years and for those aged ≥60 years at the discretion of their healthcare provider. The purpose of this study is to assess hepatitis B vaccination coverage among adults with and without diabetes mellitus.Shingles Vaccination of U.S. Adults Aged 50–59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine
In 2006, zoster vaccine live was recommended for adults aged ≥60 years. In 2011, zoster vaccine live was approved for use but not recommended for adults aged 50–59 years. This study assessed zoster vaccine live coverage among adults aged 50–59 years and ≥60 years.Seasonal Influenza Vaccination Coverage Trends Among Adult Populations, U.S., 2010–2016
Influenza is a major cause of morbidity and mortality among adults. The most effective strategy for preventing influenza is annual vaccination. However, vaccination coverage has been suboptimal among adult populations. The purpose of this study is to assess trends in influenza vaccination among adult populations.Tdap Vaccination Among Healthcare Personnel—21 States, 2013
Outbreaks of pertussis can occur in healthcare settings. Vaccinating healthcare personnel may be helpful in protecting healthcare personnel from pertussis and potentially limiting spread to others in healthcare settings.Impact of Provider Recommendation on Tdap Vaccination of Adolescents Aged 13–17 Years
Tetanus, diphtheria, and acellular pertussis (Tdap) vaccination has been recommended for adolescents in the U.S. since 2006. Information on Tdap vaccination by provider recommendation is limited. The purpose of this study is to assess recent Tdap vaccination by provider recommendation status among adolescents aged 13–17 years.National and State-Specific Shingles Vaccination Among Adults Aged ≥60 Years
Shingles (herpes zoster) causes substantial morbidity, especially among older adults. The shingles vaccine has been recommended for people aged ≥60 years since 2006. This study assessed recent shingles vaccination at national and state levels among adults aged ≥60 years.National and State-Specific Td and Tdap Vaccination of Adult Populations
The Advisory Committee on Immunization Practices recommends a single dose of tetanus, diphtheria, and acellular pertussis vaccine (Tdap) for adults followed by tetanus and diphtheria toxoids (Td) booster doses every 10 years thereafter. This study assessed recent Td and Tdap vaccination among adult populations.Influenza Vaccination Coverage Among People With High-Risk Conditions in the U.S.
During annual influenza epidemics, rates of serious illness and death are higher among those who have medical conditions, such as pulmonary disease, diabetes, or heart disease, which place them at increased risk of influenza complications. Annual influenza vaccination was recommended for people with high-risk conditions as early as 1960.Impact of Health Insurance Status on Vaccination Coverage Among Adult Populations
Underinsurance is a barrier to vaccination among children. Information on vaccination among adults aged ≥18 years by insurance status is limited. This study assesses vaccination coverage among adults aged ≥18 years in the U.S. in 2012 by health insurance status and access to care characteristics.Adult Vaccination Disparities Among Foreign-Born Populations in the U.S., 2012
Foreign-born persons are considered at higher risk of undervaccination and exposure to many vaccine-preventable diseases. Information on vaccination coverage among foreign-born populations is limited.Human Papillomavirus Vaccine Initiation and Awareness: U.S. Young Men in the 2010 National Health Interview Survey
In 2009, the quadrivalent human papillomavirus (HPV) vaccine was licensed by the U.S. Food and Drug Administration for use in men/boys aged 9–26 years. In 2009, the Advisory Committee on Immunization Practices (ACIP) provided a permissive recommendation allowing HPV vaccine administration to this group.H1N1 and Seasonal Influenza Vaccination of U.S. Healthcare Personnel, 2010
Seasonal influenza vaccination routinely has been recommended for healthcare personnel (HCP) since 1984. The influenza A (H1N1) 2009 monovalent vaccine (H1N1 vaccine) became available in the U.S. in October 2009.Influenza A (H1N1) 2009 Monovalent Vaccination Among Adults with Asthma, U.S., 2010
The 2009 pandemic influenza A (H1N1) virus (2009 H1N1) was first identified in April 2009 and quickly spread around the world. The first doses of influenza A (H1N1) 2009 monovalent vaccine (2009 H1N1 vaccine) became available in the U.S. in early October 2009. Because people with asthma are at increased risk of complications from influenza, people with asthma were included among the initial prioritized groups.Herpes Zoster Vaccination Among Adults Aged 60 Years and Older, in the U.S., 2008
Shingles (herpes zoster [HZ]) is a localized, generally painful and debilitating disease that occurs most frequently among older adults. It is caused by reactivation of varicella-zoster virus. HZ causes substantial morbidity, especially among older adults. The vaccine to prevent HZ was approved by Food and Drug Administration and recommended by the Advisory Committee for Immunization Practices for people aged ≥60 years in 2006 (these recommendations were published in 2008).
